Rh blood group system
The Rh blood group system (including the Rh factor) is one of thirty-five current human blood group systems. It is the most important blood group system after ABO. At present, the Rh blood group system consists of 50 defined blood-group antigens, among which the five antigens D, C, c, E, and e are the most important. The commonly used terms Rh factor, Rh positive and Rh negative refer to the D antigen only. Besides its role in blood transfusion, the Rh blood group system—specifically, the D antigen—is used to determine the risk of hemolytic disease of the newborn (or erythroblastosis fetalis) as prevention is the best approach to the management of this condition. As part of prenatal care, a blood test may be used to find out the blood type of a fetus. If the Rh antigen is lacking, the blood is called Rh-negative. If the antigen is present, it is called Rh-positive. When the mother is Rh-negative and the father is Rh-positive, the fetus can inherit the Rh factor from the father. This makes the fetus Rh-positive too. Problems can arise when the fetus’s blood has the Rh factor and the mother’s blood does not.
A mother who is Rh-negative may develop antibodies to an Rh-positive baby. If a small amount of the baby’s blood mixes with the mother's blood, which often happens in such situations, the mother's body may respond as if it were allergic to the baby. The mother's body may make antibodies to the Rh antigens in the baby’s blood. This means the mother has become sensitized and her antibodies may cross the placenta and attack the baby’s blood. Such an attack breaks down the fetus’s red blood cells, creating anemia (a low number of red blood cells). This condition is called hemolytic disease or hemolytic anemia. It can become severe enough to cause serious illness, brain damage, or even death in the fetus or newborn. Sensitization can occur any time the fetus’s blood mixes with the mother’s blood. It can occur if an Rh-negative woman has had a spontaneous or undetected miscarriage of a Rh positive fetus.
- 1 Rh factor
- 2 History of discoveries
- 3 Rh nomenclature
- 4 Rh system antigens
- 5 Hemolytic disease of the newborn
- 6 Population data
- 7 Inheritance
- 8 Function
- 9 Origin of RHD polymorphism
- 10 Weak D
- 11 Partial D
- 12 Rhnull phenotype
- 13 Other Rh group antigens
- 14 Rh antibodies
- 15 Erythroblastosis Fetalis
- 16 References
- 17 External links
An individual either has, or does not have, the "Rh factor" on the surface of their red blood cells. This term strictly refers only to the most immunogenic D antigen of the Rh blood group system, or the Rh− blood group system. The status is usually indicated by Rh positive (Rh+ does have the D antigen) or Rh negative (Rh− does not have the D antigen) suffix to the ABO blood type. However, other antigens of this blood group system are also clinically relevant. These antigens are listed separately (see below: Rh nomenclature). In contrast to the ABO blood group, immunization against Rh can generally only occur through blood transfusion or placental exposure during pregnancy in women.
History of discoveries
In 1939, Philip Levine and Rufus Stetson published in a first case report the clinical consequences of non-recognized Rh factor, hemolytic transfusion reaction and hemolytic disease of the newborn in its most severe form. It was recognized that the serum of the reported woman agglutinated with red blood cells of about 80% of the people although the then known blood groups, in particular ABO were matched. No name was given to this agglutinin when described for the first time. In 1940, Karl Landsteiner and Alexander S. Wiener reported a serum that also reacted with about 85% of different human red blood cells. This serum was produced by immunizing rabbits with red blood cells from Rhesus macaque. The antigen that induced this immunization was designated by them as Rh factor "to indicate that rhesus blood had been used for the production of the serum."
Based on the serologic similarities Rh factor was later also used for antigens, and anti-Rh for antibodies, found in humans such as the previously described by Levine and Stetson. Although differences between these two sera were shown already in 1942 and clearly demonstrated in 1963, the already widely used term "Rh" was kept for the clinically described human antibodies which are different from the ones related to the Rhesus monkey. This real factor found in Rhesus macaque was classified in the Landsteiner-Wiener antigen system (antigen LW, antibody anti-LW) in honor of the discoverers. It was recognized that the Rh factor was just one in a system of various antigens. Based on different models of genetic inheritance, two different terminologies were developed; both of them are still in use.
The clinical significance of this highly immunizing D antigen (i.e. Rh factor) was soon realized. Some keystones were to recognize its importance for blood transfusion including reliable diagnostic tests, and hemolytic disease of the newborn including exchange transfusion and very importantly the prevention of it by screening and prophylaxis.
The discovery of fetal cell-free DNA in maternal circulation by Holzgrieve et al. led to the noninvasive genotyping of fetal Rh genes in many countries.
The Rh blood group system has two sets of nomenclatures: one developed by Ronald Fisher and R.R. Race, the other by Wiener. Both systems reflected alternative theories of inheritance. The Fisher-Race system, which is more commonly in use today, uses the CDE nomenclature. This system was based on the theory that a separate gene controls the product of each corresponding antigen (e.g., a "D gene" produces D antigen, and so on). However, the d gene was hypothetical, not actual.
The Wiener system used the Rh–Hr nomenclature. This system was based on the theory that there was one gene at a single locus on each chromosome, each contributing to production of multiple antigens. In this theory, a gene R1 is supposed to give rise to the “blood factors” Rh0, rh’, and hr” (corresponding to modern nomenclature of the D, C and e antigens) and the gene r to produce hr’ and hr” (corresponding to modern nomenclature of the c and e antigens).
Notations of the two theories are used interchangeably in blood banking (e.g., Rho(D) meaning RhD positive). Wiener's notation is more complex and cumbersome for routine use. Because it is simpler to explain, the Fisher-Race theory has become more widely used.
DNA testing has shown that both are partially correct. There are in fact two linked genes, the RHD gene which produces a single immune specificity (anti-D) and the RHCE gene with multiple specificities (anti-C, anti-c, anti-E, anti-e). Thus, Wiener's postulate that a gene could have multiple specificities (something many did not give credence to originally) has been proven correct. On the other hand, Wiener's theory that there is only one gene has proven incorrect, as has the Fischer-Race theory that there are three genes, rather than the 2. The CDE notation used in the Fisher-Race nomenclature is sometimes rearranged to DCE to more accurately represent the co-location of the C and E encoding on the RhCE gene, and to make interpretation easier.
Rh system antigens
The proteins which carry the Rh antigens are transmembrane proteins, whose structure suggest that they are ion channels. The main antigens are D, C, E, c and e, which are encoded by two adjacent gene loci, the RHD gene which encodes the RhD protein with the D antigen (and variants) and the RHCE gene which encodes the RhCE protein with the C, E, c and e antigens (and variants). There is no d antigen. Lowercase "d" indicates the absence of the D antigen (the gene is usually deleted or otherwise nonfunctional).
Rh phenotypes are readily identified by identifying the presence or absence of the Rh surface antigens. As can be seen in the table below, most of the Rh phenotypes can be produced by several different Rh genotypes. The exact genotype of any individual can only be identified by DNA analysis. Regarding patient treatment, only the phenotype is usually of any clinical significance to ensure a patient is not exposed to an antigen they are likely to develop antibodies against. A probable genotype may be speculated on, based on the statistical distributions of genotypes in the patient's place of origin.
|Phenotype expressed on cell||Genotype expressed in DNA||Prevalence (%) †|
|Fisher-Race notation||Wiener notation|
|D+ C+ E+ c+ e+ (RhD+)||Dce/DCE||R0RZ||0.0125|
|D+ C+ E+ c+ e− (RhD+)||DcE/DCE||R2RZ||0.0687|
|D+ C+ E+ c− e+ (RhD+)||DCe/dCE||R1rY||0.0042|
|D+ C+ E+ c− e− (RhD+)||DCE/DCE||RZRZ||0.0006|
|D+ C+ E− c+ e+ (RhD+)||Dce/dCe||R0r’||0.0505|
|D+ C+ E− c− e+ (RhD+)||DCe/DCe||R1R1||17.6803|
|D+ C− E+ c+ e+ (RhD+)||DcE/Dce||R2R0||0.7243|
|D+ C− E+ c+ e− (RhD+)||DcE/DcE||R2R2||1.9906|
|D+ C− E− c+ e+ (RhD+)||Dce/Dce||R0R0||0.0659|
|D− C+ E+ c+ e+ (RhD−)||dce/dCE||rrY||0.0039|
|D− C+ E+ c+ e− (RhD−)||dcE/dCE||r’’rY||0.0001|
|D− C+ E+ c− e+ (RhD−)||dCe/dCE||r’rY||0.0001|
|D− C+ E+ c− e− (RhD−)||dCE/dCE||rYrY||<0.0001|
|D− C+ E− c+ e+ (RhD−)||dce/dCe||rr’||0.7644|
|D− C+ E− c− e+ (RhD−)||dCe/dCe||r’r’||0.0097|
|D− C− E+ c+ e+ (RhD−)||dce/dcE||rr’’||0.9235|
|D− C− E+ c+ e− (RhD−)||dcE/dcE||r’’r’’||0.0141|
|D− C− E− c+ e+ (RhD−)||dce/dce||rr||15.1020|
† Figures taken from a study performed in 1948 on a sample of 2000 people in the United Kingdom. Note that the R0 haplotype is much more common in people of sub-Saharan African origin.
|Rh Phenotype||CDE||Patients (%)||Donors (%)|
Hemolytic disease of the newborn
The hemolytic condition occurs when there is an incompatibility between the blood types of the mother and the fetus. There is also potential incompatibility if the mother is Rh negative and the father is positive. When any incompatibility is detected, the mother often receives an injection at 28 weeks gestation and at birth to avoid the development of antibodies toward the fetus. These terms do not indicate which specific antigen-antibody incompatibility is implicated. The disorder in the fetus due to Rh D incompatibility is known as erythroblastosis fetalis.
- Hemolytic comes from two words: "hemo" (blood) and "lysis" (destruction) or breaking down of red blood cells
- Erythroblastosis refers to the making of immature red blood cells
- Fetalis refers to the fetus.
When the condition is caused by the Rh D antigen-antibody incompatibility, it is called Rh D Hemolytic disease of the newborn or Rh disease. Here, sensitization to Rh D antigens (usually by feto-maternal transfusion during pregnancy) may lead to the production of maternal IgG anti-D antibodies which can pass through the placenta. This is of particular importance to D negative females at or below childbearing age, because any subsequent pregnancy may be affected by the Rh D hemolytic disease of the newborn if the baby is D positive. The vast majority of Rh disease is preventable in modern antenatal care by injections of IgG anti-D antibodies (Rho(D) Immune Globulin). The incidence of Rh disease is mathematically related to the frequency of D negative individuals in a population, so Rh disease is rare in old-stock populations of Africa and the eastern half of Asia, and the Indigenous peoples of Oceania and the Americas, but more common in other genetic groups, most especially Western Europeans, but also other West Eurasians, and to a lesser degree, native Siberians, as well as those of mixed-race with a significant or dominant descent from those (e.g. the vast majority of Latin Americans and Central Asians).
- Symptoms and signs in the fetus:
- Enlarged liver, spleen, or heart and fluid buildup in the fetus' abdomen seen via ultrasound.
- Symptoms and signs in the newborn:
- Anemia that creates the newborn's pallor (pale appearance).
- Jaundice or yellow discoloration of the newborn's skin, sclera or mucous membrane. This may be evident right after birth or after 24–48 hours after birth. This is caused by bilirubin (one of the end products of red blood cell destruction).
- Enlargement of the newborn's liver and spleen.
- The newborn may have severe edema of the entire body.
- Dyspnea or difficulty breathing.
The frequency of Rh factor blood types and the RhD neg allele gene differs in various populations.
|Population||Rh(D) Neg||Rh(D) Pos||Rh(D) Neg alleles|
|Basque people||21–36%||65%||approx 60%|
|African American||approx 7%||93%||approx 26%|
|Native Americans||approx 1%||99%||approx 10%|
|African descent||less 1%||over 99%||3%|
|Asian||less 1%||over 99%||1%|
If both of a child's parents are Rh negative, the child will definitely be Rh negative. Otherwise the child may be Rh positive or Rh negative, depending on the parents' specific genotypes. 
The D antigen is inherited as one gene (RHD) (on the short arm of the first chromosome, p36.13–p34.3) with various alleles. Though very much simplified, one can think of alleles that are positive or negative for the D antigen. The gene codes for the RhD protein on the red cell membrane. D− individuals who lack a functional RHD gene do not produce the D antigen, and may be immunized by D+ blood.
The epitopes for the next 4 most common Rh antigens, C, c, E and e are expressed on the highly similar RhCE protein that is genetically encoded in the RHCE gene, also found on chromosome 1. It has been shown that the RHD gene arose by duplication of the RHCE gene during primate evolution. Mice have just one RH gene.
The RHAG gene, responsible for encoding Rh-associated glycoprotein (RhAG) is found on chromosome 6a.
The polypeptides produced from the RHD and RHCE genes form a complex on the red blood cell membrane with the Rh-associated glycoprotein.
On the basis of structural homology it has been proposed that the product of RHD gene, the RhD protein, is a membrane transport protein of uncertain specificity (CO2 or NH3) and unknown physiological role. The three-dimensional structure of the related RHCG protein and biochemical analysis of the RhD protein complex indicates that the RhD protein is one of three subunits of an ammonia transporter. Three recent studies have reported a protective effect of the RhD-positive phenotype, especially RhD heterozygosity, against the negative effect of latent toxoplasmosis on psychomotor performance in infected subjects. RhD-negative compared to RhD-positive subjects without anamnestic titres of anti-Toxoplasma antibodies have shorter reaction times in tests of simple reaction times. And conversely, RhD-negative subjects with anamnestic titres (i.e. with latent toxoplasmosis) exhibited much longer reaction times than their RhD-positive counterparts. The published data suggested that only the protection of RhD-positive heterozygotes was long term in nature; the protection of RhD-positive homozygotes decreased with duration of the infection while the performance of RhD-negative homozygotes decreased immediately after the infection.
Origin of RHD polymorphism
||This section possibly contains original research. (December 2009)|
For a long time, the origin of RHD polymorphism was an evolutionary enigma. Before the advent of modern medicine, the carriers of the rarer allele (e.g. RhD-negative women in a population of RhD positives or RhD-positive men in a population of RhD negatives) were at a disadvantage as some of their children (RhD-positive children born to preimmunised RhD-negative mothers) were at a higher risk of fetal or newborn death or health impairment from hemolytic disease. It was suggested that higher tolerance of RhD-positive heterozygotes against Toxoplasma-induced impairment of reaction time  and Toxoplasma-induced increase of risk of traffic accident could counterbalance the disadvantage of the rarer allele and could be responsible both for the initial spread of the RhD allele among the RhD-negative population and for a stable RhD polymorphism in most human populations. It was also suggested that differences in the prevalence of Toxoplasma infection between geographical regions (0–95%) could also explain the striking variation in the frequency of RhD-negative alleles between populations. According to some parasitologists  it is possible that the better psychomotor performance of RhD-negative subjects in the Toxoplasma-free population could be the reason for spreading of the “d allele” (deletion) in the European population. In contrast to the situation in Africa and certain (but not all) regions of Asia, the abundance of wild cats (definitive hosts of Toxoplasma gondii) in Europe was very low before the advent of the domestic cat.
In serologic testing, D positive blood is easily identified. Units which are D negative are often retested to rule out a weaker reaction. This was previously referred to as Du, which has been replaced.:322 By definition, weak D phenotype is characterized by negative reaction with anti-D reagent at immediate spin (IS), negative reaction after 37 °C incubation, and positive reaction at anti-human globulin (AHG) phase. Weak D phenotype can occur in several ways. In some cases, this phenotype occurs because of an altered surface protein that is more common in people of European descent. An inheritable form also occurs, as a result of a weakened form of the R0 gene. Weak D may also occur as "C in trans", whereby a C gene is present on the opposite chromosome to a D gene (as in the combination R0r', or "Dce/dCe"). The testing is difficult, since using different anti-D reagents, especially the older polyclonal reagents, may give different results.
The practical implication of this is that people with this sub-phenotype will have a product labeled as "D positive" when donating blood. When receiving blood, they are sometimes typed as a "D negative", though this is the subject of some debate. Most "Weak D" patients can receive "D positive" blood without complications.:323 However, it is important to correctly identify the ones that have to be considered D+ or D−. This is important, since most blood banks have a limited supply of "D negative" blood and the correct transfusion is clinically relevant. In this respect, genotyping of blood groups has much simplified this detection of the various variants in the Rh blood group system.
It is important to differentiate weak D (due to a quantitative difference in the D antigen) from partial D (due to a qualitative difference in the D antigen). Simply put, the weak D phenotype is due to a reduced number of D antigens on a red blood cell. In contrast, the partial D phenotype is due to an alteration in D-epitopes. Thus, in partial D, the number of D antigens is not reduced but the protein structure is altered. These individuals, if alloimmunized to D, can produce an anti-D antibody. Therefore, partial D patients who are donating blood should be labeled as D-positive but, if receiving blood, they should be labeled as D-negative and receive D-negative units.
In the past, partial D was called 'D mosaic' or 'D variant.' Different partial D phenotypes are defined by different D epitopes on the outer surface of the red blood cell membrane. More than 30 different partial D phenotypes have been described.
Rhnull individuals have no Rh antigens (no Rh or RhAG) on their red blood cells. This condition is rare. As a consequence of Rh antigen absence, Rhnull red blood cells also lack LW and Fy5 and show weak expression of S, s, and U antigens. Red blood cells lacking Rh/RhAG proteins have structural abnormalities (such as stomatocytosis) and cell membrane defects that can result in hemolytic anemia.
Other Rh group antigens
Currently, 50 antigens have been described in the Rh group system; among those described here, the D, C, c, E and e antigens are the most important. The others are much less frequently encountered or are rarely clinically significant. Each is given a number, though the highest assigned number (CEST or RH57 according to the ISBT terminology) is not an accurate reflection of the antigens encountered since many (e.g. Rh38) have been combined, reassigned to other groups, or otherwise removed.:324
Rh antibodies are IgG antibodies which are acquired through exposure to Rh-positive blood (generally either through pregnancy or transfusion of blood products). The D antigen is the most immunogenic of all the non-ABO antigens. Approximately 80% of individuals who are D-negative and exposed to a single D-positive unit will produce an anti-D antibody. The percentage of alloimmunization is significantly reduced in patients who are actively exsanguinating (some say to approx 15%)
All Rh antibodies except D display dosage (antibody reacts more strongly with red cells homozygous for an antigen than cells heterozygous for the antigen (EE stronger reaction vs Ee).
If anti-E is detected, the presence of anti-c should be strongly suspected (due to combined genetic inheritance). It is therefore common to select c-negative and E-negative blood for transfusion patients who have an anti-E. Anti-c is a common cause of delayed hemolytic transfusion reactions.
Rh agglutinins (antibodies) are capable of causing hemolytic transfusion reactions with extravascular hemolysis. They may also result in severe hemolytic disease of the fetus and newborn (HDFN or HDN) when a Rh negative mother carries a Rh positive fetus, as the Rh agglutinogens from the fetus trigger an immune response from the mother, producing Rh agglutinins and causing the blood of the fetus to agglutinate (coagulate). Symptoms in the newborn usually include an abnormally large liver or spleen, anemia or low red blood cell count, and in serious cases, swelling of the skin or internal organs. Treatment of the mother with Rh-immunoglobulin during term may help decrease the complement cascade and therefore lower the severity of the fetus's symptoms.
- Levine P, Stetson RE (1939). "An unusual case of intragroup agglutination". JAMA 113: 126–7. doi:10.1001/jama.1939.72800270002007a.
- Landsteiner K, Wiener AS (1940). "An agglutinable factor in human blood recognized by immune sera for rhesus blood". Proc Soc Exp Biol Med 43: 223–4. doi:10.3181/00379727-43-11151.
- Landsteiner K, Wiener AS (1941). "Studies on an agglutinogen (Rh) in human blood reacting with anti-rhesus sera and with human isoantibodies". J Exp Med 74 (4): 309–320. doi:10.1084/jem.74.4.309. PMC 2135190. PMID 19871137.
- Avent ND, Reid ME (2000). "The Rh blood group system: a review". Blood 95 (2): 375–387. PMID 10627438.
- Scott ML (2004). "The complexities of the Rh system". Vox sang 87 ((Suppl. 1)): S58–S62. doi:10.1111/j.1741-6892.2004.00431.x.
- Weiner, Alexander S. (1 February 1949). "Genetics and Nomenclature of the Rh–Hr Blood Types". Antonie van Leeuwenhoek (Netherlands: Springerlink) 15 (1): 17–28. doi:10.1007/BF02062626. ISSN 0003-6072. Retrieved 6 November 2010.
- "dbRBC - Blood Group Antigen Gene Mutation Database". www.ncbi.nlm.nih.gov. Retrieved 2010-06-15.
- "RHD Rh blood group, D antigen [Homo sapiens] - Gene Result". nlm.nih.gov. Retrieved 2010-06-15.
- "RHCE Rh blood group, CcEe antigens [Homo sapiens] - Gene Result". nlm.nih.gov. Retrieved 2010-06-15.
- Race RR, Mourant AE (1948). "The Rh Chromosome Frequencies in England" (PDF). Blood (USA: American Society of Haematology) 3 (6): 689–695. PMID 18860341. Retrieved 2010-11-14.
- Canatan, Duran; Nilgün Acar; Banu Kiliç (1999). "Rh Subgroups and Kell Antigens in Patients With Thalassemia and in Donors in Turkey" (PDF). Turkish Journal of Medical Sciences (Tübitak) 29: 155–7. Retrieved 2008-10-17.
- Mack, Steve (March 21, 2001). "Re: Is the RH negative blood type more prevalent in certain ethnic groups?". MadSci Network.
- Touinssi M, Chiaroni J, Degioanni A, De Micco P, Dutour O, Bauduer F (2004). "Distribution of rhesus blood group system in the French basques: a reappraisal using the allele-specific primers PCR method". Human Heredity 58 (2): 69–72. doi:10.1159/000083027. PMID 15711086.
- "ABO inheritance patterns". Inheritance patterns of blood groups. Australian Red Cross Blood Service. Retrieved 30 October 2013.
- Wagner FF, Flegel WA (Mar 2002). "RHCE represents the ancestral RH position, while RHD is the duplicated gene". Blood 99 (6): 2272–3. doi:10.1182/blood-2001-12-0153. PMID 11902138.
- Mais, DD. ASCP Quick Compendium of Clinical Pathology, 2nd Ed. Chicago, ASCP Press, 2009.
- Kustu S, Inwood W (2006). "Biological gas channels for NH3 and CO2: evidence that Rh (rhesus) proteins are CO2 channels". Transfusion Clinique et Biologique 13 (1-2): 103–110. doi:10.1016/j.tracli.2006.03.001. PMID 16563833.
- Biver S, Scohy S, Szpirer J, Szpirer C, André B, Marini AM (2006). "Physiological role of the putative ammonium transporter RhCG in the mouse.". Transfusion Clinique et Biologique 13 (1-2): 167–8. doi:10.1016/j.tracli.2006.03.003. PMID 16564721.
- Gruswitz F, Chaudhary S, Ho JD, Schlessinger A, Pezeshki B, Ho CM, Sali A, Westhoff CM, Stroud RM (2010). "Function of human Rh based on structure of RhCG at 2.1 A". Proceedings of the National Academy of Sciences 107 (21): 9638–9643. doi:10.1073/pnas.1003587107. PMC 2906887. PMID 20457942.
- Westhoff CM (2007). "The Structure and Function of the Rh Antigen Complex". Seminars in Hematology 44 (1): 42–50. doi:10.1053/j.seminhematol.2006.09.010. PMC 1831834. PMID 17198846.
- Novotná M, Havlícek J, Smith AP, Kolbeková P, Skallová A, Klose J, Gasová Z, Písacka M, Sechovská M, Flegr J (2008). "Toxoplasma and reaction time: Role of toxoplasmosis in the origin, preservation and geographical distribution of Rh blood group polymorphism" (PDF). Parasitology 135 (11): 1253–61. doi:10.1017/S003118200800485X. PMID 18752708.
- Flegr J, Novotná M, Lindová J, Havlícek J (2008). "Neurophysiological effect of the Rh factor. Protective role of the RhD molecule against Toxoplasma-induced impairment of reaction times in women" (PDF). Neuroendocrinology Letters 29 (4): 475–481. PMID 18766148.
- Flegr J, Klose J, Novotná M, Berenreitterová M, Havlícek J (2009). "Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study.". BMC Infect. Dis. 9: 72. doi:10.1186/1471-2334-9-72. PMC 2692860. PMID 19470165.
- Haldane JBF (1942). "Selection against heterozygosis in Man.". Eugenics 11: 333–340. doi:10.1111/j.1469-1809.1941.tb02297.x.
- Fisher RA, Race RR, Taylor GL. (1944). "Mutation and the Rhesus reaction". Nature 153: 106. doi:10.1038/153106b0.
- Li CC (1953). "Is the Rh facing a crossroad? A critique of the compensation effect.". Am Naturalist. 87: 257–261. doi:10.1086/281782.
- Brecher ME (2005). Technical Manual (15th ed.). Bethesda MD: American Association of Blood Banks. ISBN 1-56395-196-7.
- Cartron, J.P. (December 1999). "RH blood group system and molecular basis of Rh-deficiency". Best Practice & Research Clinical Haematology 12 (4): 655–689. doi:10.1053/beha.1999.0047. PMID 10895258.
- "Erythroblastosis Fetalis". Erythroblastosis Fetalis. The Free Dictionary by Farlax. Retrieved 30 May 2015.
- Rh at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH
- Article commemorating the first appearance of the Rh factor in the New York Times